Author

R. March

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 4 Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 3 Research Focus:drug response / drug discovery· 2 Research Focus:gene regulatory network inference· 2 Organism:human· 2 Approach:statistical model· 2 Assay:whole-genome sequencing· 2 Research Focus:cancer & tumor microenvironment· 1

Frequent Co-Authors

A. Barreiro· 3 shared A. Fernandez· 3 shared A. Prenafeta· 3 shared C. Garriga· 3 shared E. Pradenas· 3 shared J. Blanco· 3 shared S. Marfil· 3 shared A. Ewing· 2 shared

Activity by Year

2020-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

A. Barreiro

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Fetal protection against bovine viral diarrhea virus types 1 and 2 after vaccination of the dam with the DIVENCE vaccine

E. Taberner, M. Gibert, C. Montbrau, I. Munoz, J. Mallorqui, H. Santo Tomas, A. Prenafeta, R. March

This study shows that vaccinating pregnant heifers with DIVENCE reduces fetal BVDV infection and clinical signs after challenge with BVDV-1 or BVDV-2.

bioRxiv · Apr 12, 2024 · PreprintImmunology

Divergent trajectories to structural diversity impact patient survival in high grade serous ovarian cancer

A. Ewing, A. Meynert, R. Silk, S. Aitken, D. P. Bendixsen, M. Churchman, S. L. Brown, A. Hamdan, J. Mattocks, G. R. Grimes, T. Ballinger, R. L. Hollis, C. S. Herrington, J. P. Thomson, K. Sherwood, , C. A. Semple

The paper identifies two divergent structural variation trajectories in HGSOC that impact patient survival and reveals novel candidate driver genes and mtDNA mutations associated with prognosis.

bioRxiv · Jan 12, 2024Cancer Biology

Immunogenicity and safety in pigs of PHH-1V, a SARS-CoV-2 RBD fusion heterodimer vaccine candidate

A. Moros, A. Prefaneta, A. Barreiro, E. Perozo, A. Fernandez, M. Canete, L. Gonzalez, C. Garriga, E. Pradenas, S. Marfil, J. Blanco, P. Cebollada-Rica, M. Sistere-Oro, A. Meyerhans, T. Prat Cabanas, , L. Ferrer

This study evaluates the immunogenicity and safety of PHH-1V, a SARS-CoV-2 RBD fusion vaccine in pigs, showing a robust immune response and good safety profile.

bioRxiv · Jan 19, 2023Immunology

Preclinical evaluation of PHH-1V vaccine candidate against SARS-CoV-2 in non-human primates

A. Prenafeta, G. Bech-Sabat, S. Moros, A. Barreiro, A. Fernandez, M. Canete, M. Roca, L. Gonzalez, C. Garriga, J. Confais, M. Toussenot, H. Contamin, A. Pizzorno, M. Rosa-Calatrava, E. Pradenas, , L. Ferrer

This study evaluates the PHH-1V vaccine candidate against SARS-CoV-2 in non-human primates, showing high antibody levels, balanced cellular immunity, and reduced viral load.

bioRxiv · Dec 13, 2022Immunology

Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2

A. Barreiro, A. Prenafeta, G. Bech-Sabat, M. Roca, E. Perozo, R. March, L. Gonzalez-Gonzalez, L. Madrenas, J. Corominas, A. Fernandez, A. Moros, M. Molas, T. Pentinat-Pelegrin, C. Panosa, A. Moreno, , Barr

This paper evaluates a recombinant RBD fusion heterodimer vaccine in mice, showing 100% efficacy against SARS-CoV-2 variants and neutralizing antibodies.

bioRxiv · Nov 22, 2021Immunology

Structural variants at the BRCA1/2 loci are a common source of homologous repair deficiency in high grade serous ovarian carcinoma

A. Ewing, A. Meynert, M. Churchman, G. R. Grimes, R. L. Hollis, C. S. Herrington, T. Rye, C. Bartos, I. Croy, M. Ferguson, M. Lennie, T. McGoldrick, N. McPhail, N. Siddiqui, S. Dowson, , C. A. Semple

This study identifies large structural variants as a significant source of homologous repair deficiency in high-grade serous ovarian carcinoma, beyond known SNVs and indels at BRCA1/2.

bioRxiv · May 11, 2020Cancer Biology